AUTOTUMOUR REACTIVE T-CELL CLONES AMONG TUMOR-INFILTRATING T-LYMPHOCYTES IN B-CELL NON-HODGKINS-LYMPHOMAS

被引:19
作者
SHI, I
BONNEFOIX, T
HEUZELEVACON, F
JACOB, MC
LEROUX, D
GRESSIN, R
SOTTO, MF
CHAFFANJON, P
BENSA, JC
SOTTO, JJ
机构
[1] HOP A MICHALLON,SERV HEMATOL,RECH IMMUNOPATHOL TUMORALE LAB,GRENOBLE,FRANCE
[2] FAC MED GRENOBLE,CTR TRANSFUS SANGUINE,GRENOBLE,FRANCE
[3] FAC MED GRENOBLE,CYTOGENET LAB,GRENOBLE,FRANCE
关键词
TUMOR-INFILTRATING T-LYMPHOCYTES; PROLIFERATION; CYTOTOXICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; B LYMPHOMA;
D O I
10.1111/j.1365-2141.1995.tb05204.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Seventy-three T-cell clones (TCC) were established from tumour-infiltrating lymphocytes-T (TIL-T) derived from lymph nodes involved by B-cell non-Hodgkin's lymphomas (B-NHL) in nine patients with different histological subtypes and clinical stages. 40 TCC (55%) expressed the CD25 Ag and were also able to proliferate in the presence of irradiated autologous B-NHL cells. Among them, 23 autotumour (AuTu) proliferative TCC were found not to proliferate to autologous EBV-transformed B-cell lines, indicating that the proliferative reactivity of these TCC was preferentially directed at autologous B-NHL cells, Tested against autologous B-NHL cells, only three AuTu proliferative TCC (CD8(+)) showed a significant level of cytotoxicity (specific lysis > 15%), In blocking experiments, the AuTu proliferative reactivity of three TCC from one patient was strongly inhibited by anti-DR and anti-DQ mAbs, whereas that of three TCC from another patient was not affected by either anti-MHC class I or class II (DR, DP, DQ) mAbs. These findings suggest that the recognition of autologous B-NHL cells by AuTu proliferative TCC may occur through MHC-restricted as well as MHC-unrestricted mechanisms.
引用
收藏
页码:837 / 843
页数:7
相关论文
共 27 条
[1]   SPECIFIC, MAJOR HISTOCOMPATIBILITY COMPLEX - UNRESTRICTED RECOGNITION OF TUMOR-ASSOCIATED MUCINS BY HUMAN CYTO-TOXIC T-CELLS [J].
BARND, DL ;
LAN, MS ;
METZGAR, RS ;
FINN, OJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (18) :7159-7163
[2]   DETECTION, ISOLATION AND FUNCTIONAL-STUDIES OF CD25+ T-CELLS IN LYMPH-NODES INVOLVED BY B-CELL NON-HODGKINS-LYMPHOMAS [J].
BONNEFOIX, T ;
CLARET, E ;
PICCINNI, MP ;
JACOB, MC ;
ZHENG, X ;
SOTTO, JJ .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1991, 34 (01) :91-100
[3]   LIMITING DILUTION ANALYSIS OF THE FREQUENCY OF IL2 RESPONSIVE T-CELLS IN LYMPH-NODES INVOLVED BY B-CELL NON-HODGKINS LYMPHOMAS [J].
BONNEFOIX, T ;
PICCINNI, MP ;
JACOB, MC ;
PEGOURIE, B ;
SOTTO, JJ .
LEUKEMIA RESEARCH, 1989, 13 (04) :323-329
[4]   THE STANDARD CHI-2 TEST USED IN LIMITING DILUTION ASSAYS IS INSUFFICIENT FOR ESTIMATING THE GOODNESS-OF-FIT TO THE SINGLE-HIT POISSON MODEL [J].
BONNEFOIX, T ;
SOTTO, JJ .
JOURNAL OF IMMUNOLOGICAL METHODS, 1994, 167 (1-2) :21-33
[5]  
BRAZIEL RM, 1985, BLOOD, V66, P128
[6]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[7]  
CLARET E, 1992, LEUKEMIA, V6, P820
[8]   THE CELLULAR CONTENT OF NON HODGKIN LYMPHOMAS - A COMPREHENSIVE ANALYSIS USING MONOCLONAL-ANTIBODIES AND OTHER SURFACE MARKER TECHNIQUES [J].
HABESHAW, JA ;
BAILEY, D ;
STANSFELD, AG ;
GREAVES, MF .
BRITISH JOURNAL OF CANCER, 1983, 47 (03) :327-351
[9]   THE USE OF GENE-MODIFIED TUMOR-INFILTRATING LYMPHOCYTES FOR CANCER-THERAPY [J].
HWU, P ;
ROSENBERG, SA .
GENE THERAPY FOR NEOPLASTIC DISEASES, 1994, 716 :188-199
[10]  
HYSSEL H, 1984, J EXP MED, V160, P239